Articles Referencing OSIR
Pipeline Progress at Gilead - Analyst Blog
5/16/2013, 2:29 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences, Inc. ( GILD ) recently
presented encouraging data on its pipeline candidate idelalisib
(formerly GS-1101) from a phase II study (study 101-08: n=64). The
study is... Read >>
Osiris Loss In-Line with Expectations - Analyst Blog
5/8/2013, 6:24 pm from Zacks.com in Investing, Business, Stocks
Osiris Loss In-Line with Expectations Osiris Therapeutics Inc. ( OSIR ) reported a
first-quarter 2013 loss of 8 cents per share, in-line with the
Zacks Consensus Estimate but wider than... Read >>
Affymetrix Reports Disappointing 1Q - Analyst Blog
5/2/2013, 8:49 am from Zacks.com in Investing, Business, Stocks
Global genetic devices maker, Affymetrix Inc.
's ( AFFX )
first-quarter 2013 adjusted loss per share of 1 cent was wider than
the Zacks Consensus Estimate of break-even earnings. The... Read >>
Vertex Loss Lower, Kalydeco Outlook Up - Analyst Blog
5/1/2013, 8:49 am from Zacks.com in Investing, Business, Stocks
Vertex Pharmaceuticals Inc. ( VRTX ) posted a loss
of 12 cents per share (including stock-based compensation expense)
in the first quarter of 2013, well below the year-ago earnings of
41... Read >>
Double Setback for Gilead - Analyst Blog
4/30/2013, 3:47 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences, Inc ( GILD ) suffered two
successive setbacks when the US Food and Drug Administration (FDA)
issued complete response letters (CRLs) to the company's HIV
candidates,... Read >>
Geron Narrows Loss; Cuts Jobs - Analyst Blog
4/29/2013, 10:03 am from Zacks.com in Investing, Business, Stocks
Geron Corporation ( GERN ) posted a net
loss of 9 cents per share in the first quarter of 2013, wider than
the Zacks Consensus Estimate of a loss of 8 cents but narrower than
the year-ago... Read >>
Biogen's Earnings Surpass Expectations - Analyst Blog
4/25/2013, 12:14 pm from Zacks.com in Investing, Business, Earnings, Stocks
Biogen Idec ( BIIB ) reported first
quarter earnings per share of $1.96, well above the Zacks Consensus
Estimate of $1.57 and 41% above the year-ago earnings. First
quarter 2013 revenues... Read >>
Sanofi's Vaccine Gets EU Approval - Analyst Blog
4/22/2013, 12:09 pm from Zacks.com in Investing, Business, Stocks
Sanofi 's ( SNY ) vaccines
division, Sanofi Pasteur, announced that the European Commission
(EC) has approved its 6-in-1 pediatric vaccine Hexyon/Hexacima
(DTaP-IPV-Hib-HepBvaccine).
The... Read >>
Vertex CF Candidate Impresses - Analyst Blog
4/19/2013, 3:40 pm from Zacks.com in Investing, Business, Stocks
Vertex Pharmaceuticals Incorporated ( VRTX ) received a huge
boost with the company reporting impressive phase II data on its
cystic fibrosis (CF) candidate, VX-661. The randomized,... Read >>
Osiris Therapeutics, Inc. Enters Oversold Territory - Tale of the Tape
4/12/2013, 12:06 pm from Zacks.com in Investing, Investing Ideas, Stocks
Osiris Therapeutics, Inc. 's ( OSIR ) share price has
entered into oversold territory with a stochastic value of 17.9012.
The Zacks Consensus Estimate on the company's loss for year... Read >>
Alkermes Announces Restructuring Plan - Analyst Blog
4/11/2013, 5:06 pm from Zacks.com in Investing, Business, Stocks
Alkermes plc ( ALKS ) recently
announced the approval of a restructuring plan by the board of
directors related to its manufacturing facility at Athlone,
Ireland. Alkermes Pharma Ireland... Read >>
Affymetrix to Disappoint in 1Q - Analyst Blog
4/10/2013, 9:10 am from Zacks.com in Investing, Business, Stocks
Genetic products company, Affymetrix Inc. ( AFFX ) provided a
disappointing guidance for its 2013 first-quarter results, based on
available preliminary financial data. The company will... Read >>
Patients Dosed in Arena Study - Analyst Blog
4/9/2013, 6:09 pm from Zacks.com in Investing, Business, Stocks
Arena Pharmaceuticals, Inc. ( ARNA ) recently
announced that patient dosing in a randomized, double-blind and
placebo-controlled phase I study being conducted on APD334 has
commenced. The... Read >>
Sanofi Unveils Bond Issue Pricing - Analyst Blog
4/9/2013, 4:08 pm from Zacks.com in Investing, Business, Stocks
Sanofi ( SNY ) successfully
conducted a global bond market transaction, thereby issuing notes
worth $1.5 billion. Sanofi intends to utilize the proceeds from the
transaction for general... Read >>
ISIS Initiates ISIS-APOA Study - Analyst Blog
4/8/2013, 6:09 pm from Zacks.com in Investing, Business, Stocks
Isis Pharmaceuticals, Inc. ( ISIS ) recently
announced the initiation of a phase I study on an antisense
candidate targeting apolipoprotein(a), ISIS-APOA, for treating
patients suffering... Read >>